Cyclosporine therapy during the COVID-19 pandemic

J Am Acad Dermatol. 2020 Aug;83(2):e151-e152. doi: 10.1016/j.jaad.2020.04.153. Epub 2020 May 4.

Authors

Lidia Rudnicka¹, Paulina Glowacka², Mohamad Goldust³, Mariusz Sikora², Marta Sar-Pomian², Adriana Rakowska², Zbigniew Samochocki², Malgorzata Olszewska²

Affiliations

¹ Department of Dermatology, Medical University of Warsaw, Warsaw, Poland. Electronic address: lidiarudnicka@gmail.com.
² Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
³ Department of Dermatology, University of Rome G. Marconi, Rome, Italy; Department of Dermatology, University Medical Center Mainz, Mainz, Germany; Department of Dermatology, University Hospital Basel, Basel, Switzerland.

No abstract available

Publication types

Letter

MeSH terms

Autoimmune Diseases / drug therapy*
Betacoronavirus / drug effects
Betacoronavirus / immunology*
COVID-19
Coronavirus Infections / epidemiology
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control*
Coronavirus Infections / virology
Cyclosporins / pharmacology*
Cyclosporins / therapeutic use
Humans
Middle East Respiratory Syndrome Coronavirus / drug effects
Middle East Respiratory Syndrome Coronavirus / immunology
Pandemics / prevention & control*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control*
Pneumonia, Viral / virology
SARS-CoV-2
Severe Acute Respiratory Syndrome / epidemiology
Severe Acute Respiratory Syndrome / immunology
Severe Acute Respiratory Syndrome / prevention & control
Severe Acute Respiratory Syndrome / virology
Severe acute respiratory syndrome-related coronavirus / drug effects
Severe acute respiratory syndrome-related coronavirus / immunology
Virus Replication / drug effects*

Substances

Cyclosporins